New drug cocktail targets deadliest blood cancers
NCT ID NCT07632170
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether adding selinisole to standard chemotherapy drugs (azacitidine and venetoclax) can improve outcomes for people with newly diagnosed, high-risk myeloid tumors that have a TP53 mutation. These tumors are aggressive and hard to treat. The study will measure how many patients achieve remission and how long they live, while also tracking side effects. About 30 participants will receive the drug combination in cycles until their disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selinisole (also known as selinexor) combined with azacitidine and venetoclax
- What this could lead to
- If successful, this combination could offer a more effective treatment option for people with aggressive myeloid tumors that have a TP53 mutation, potentially improving survival.
- What could go wrong
- This is a small, early-phase study without a comparison group, so results may not be definitive. The drug combination can cause significant side effects, and not all patients may benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking union medical college hospital
Beijing, Shuangfuyuan, NO I., China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?